Israeli scientists from Bar-Ilan University have found that gestational diabetes can be diagnosed as early as the first trimester of pregnancy — months earlier than typically detected – through the use of gut microbes. The new study, led by Prof. Omry Koren, of the Azrieli Faculty of Medicine of Bar-Ilan University, and a team of Israeli and international researchers, is one of the first to show reliable prediction of GDM months before it is typically diagnosed.
This is the second time this month alone that Israeli scientists have found a new health benefit from gut microbes. Scientists from the Weizmann Institute of Science in Israel and the German Cancer Research Center (DKFZ), together with colleagues from Israel, Germany and the USA, found that the gut microbiome may modulate the efficacy of CAR-T cellular immunotherapy in patients with B-cell lymphomas.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Gestational diabetes mellitus (GDM) is a condition in which women without diabetes develop glucose intolerance during pregnancy. GDM, which plagues approximately 10% of pregnant women worldwide, is currently diagnosed in the second trimester of pregnancy.
There are marked differences in the first trimester gut microbiota (the bacterial population found in the guts of humans and animals) of women who do and do not later develop gestational diabetes. These differences are associated with inflammatory markers, with women who develop gestational diabetes exhibiting higher inflammation and lower levels of beneficial metabolites.
In the study fecal and serum samples were collected from pregnant women during their first trimester. The microbiota, metabolite, inflammation, and hormone profiles were characterized. Diet, smoking, and other lifestyle habits were recorded, and clinical/medical data was compiled from digital health records. Using the results of these characterizations, combined with other collected data, Prof. Yoram Louzoun, from the Department of Mathematics and Gonda (Goldschmied) Multidisciplinary Brain Research Center, built a machine learning model that can accurately predict which women would and would not go on to develop gestational diabetes.
The researchers then demonstrated in animal models that transferring the first trimester feces of women that went on to develop gestational diabetes results in the transfer of the diabetes phenotype to germ-free mice, suggesting that the gut microbiome has a role in mediating disease development. The study findings are not population specific. The microbiome model, for example, could predict GDM in Chinese women, and the mice results were replicated in Finnish and American cohorts.
“Recognition of women at risk of gestational diabetes at an early stage of pregnancy may allow specific recommendations for the prevention of the disease — currently by lifestyle modification and in the future perhaps by specific pre, pro, and postbiotic supplementation,” says Prof. Koren.
If gestational diabetes can be prevented, there would be a major reduction in adverse outcomes of gestational diabetes, for the mother and offspring, in both the short and long term, benefiting families worldwide.
